Lupin Launches Liraglutide in US Amid FDA Regulatory Hurdle

Lupin has launched Liraglutide injection in the US market, a key move to tap into a high-value segment with estimated annual sales of $350 million. The launch strengthens its portfolio of complex generics and enhances its growth potential in one of the world’s most competitive pharmaceutical markets. However, this progress is tempered by regulatory challenges. The US FDA concluded an inspection of Lupin’s Pithampur Unit-2 with an ‘Official Action Indicated’ (OAI) classification and issued four observations, signaling significant compliance concerns that may require corrective actions. While the Liraglutide launch offers strong revenue potential, the OAI status could impact operations and increase compliance costs. Investors will watch closely how Lupin balances its market expansion with resolving regulatory issues—key to its long-term success in the US.